CTLA4 and neoplasm: However, within all tumor types, there was inter-patient variability in LAG-3 expression level.<h4>Conclusions</h4>Prospective studies are therefore needed to determine if high levels of the LAG-3 checkpoint are responsible for resistance to anti-PD-1/PD-L1 or anti-CTLA-4 antibodies.